Biological activities of C1 inhibitor

Molecular Immunology

Volumn 45, Issue 16, 2008, Pages 4057-4063

  Davis, Alvin E ^a   Mejia, Pedro ^a   Lu, Fengxin ^a  

^a CENTER FOR BLOOD RESEARCH   (United States)

Author keywords

Complement system; Gram negative sepsis; Hyperacute transplant rejection; Ischemia reperfusion injury; Leukocyte rolling; Plasma kallikrein kinin system; Serpins

Indexed keywords

BLOOD CLOTTING FACTOR 12A; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1S INHIBITOR; KALLIKREIN; PEPTIDE HYDROLASE; PROTEINASE; SERINE PROTEINASE INHIBITOR;

ANIMAL; HUMAN; METABOLISM; PROTEIN BINDING; REPERFUSION INJURY; REVIEW; SEPTIC SHOCK;

ANIMALS; COMPLEMENT C1; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C1 INHIBITOR PROTEIN; ENDOPEPTIDASES; FACTOR XIIA; HUMANS; KALLIKREINS; PEPTIDE HYDROLASES; PROTEIN BINDING; REPERFUSION INJURY; SERPINS; SHOCK, SEPTIC;

EID: 55949106824     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.06.028     Document Type: Review

References (106)

1. Akita, N., Nakase, H., Kaido, T., Kanemoto, Y., Sakaki, T., 2003. Protective effect of C1 esterase inhibitor on reperfusion injury in the rat middle cerebral artery occlusion model. Neurosurgery 52, 395-400.
2. Aoki, N., Moroi, M., Matsuda, M., Tachiya, K., 1977. The behavior of alpha2-plasmin inhibitor in fibrinolytic states. J. Clin. Invest. 60, 361-369.
3. Barton, P.A., Warren, J.S., 1993. Complement component C5 modulates the systemic tumor necrosis factor response in murine endotoxic shock. Infect. Immun. 61, 1474-1481.
4. Bauernschmitt, R., Bohrer, H., Hagl, S., 1998. Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med. 24, 635-638.
5. Beinrohr, L., Harmat, V., Dobo, J., Zsolt, L., Gal, P., Zavodszky, P., 2007. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J. Biol. Chem. 282, 21100-21209.
6. Bergamaschini, L., Gobbo, G., Gatti, S., Caccamo, L., Prato, P., Maggioni, M., Braidotti, P., Di Stefano, R., Fassati, L.R., 2001. Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver. Clin. Exp. Immunol. 126, 412-420.
7. Bock, S.C., Skriver, K., Nielsen, E., Thogersen, H.C., Wiman, B., Donaldson, V.H., Eddy, R.L., Marrinan, J., Radziejewska, E., Huber, R., Shows, T.B., Magnussen, S., 1986. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 25, 4292-4301.
8. Buerke, M., Murohara, T., Lefer, A.M., 1995. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91, 393-402.
9. Buerke, M., Prufer, D., Dahm, M., Oelert, H., Meyer, J., Darius, H., 1998. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemicmyocardium from reperfusion injury. J. Pharmacol. Exp. Ther. 286, 429-438.
10. Cai, S., Davis III, A.E., 2003. Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion. J. Immunol. 171, 4786-4791.
11. Cai, S., Dole, V., Bergmeier, W., Scafidi, J., Feng, H., Wagner, D.D., Davis III, A.E., 2005. A direct role for C1 inhibitor in leukocyte adhesion. J. Immunol. 174, 6462-6466.
12. Caliezi, C., Zeerleder, S., Redondo, M., Regli, B., Rothen, H.U., Zurcher-Zenklusen, R., Rieben, R., Devay, J., Hack, C.E., Lammle, B., Wuilemin, W.A., 2002. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit. Care Med. 30, 1722-1728.
13. Chang, N.-S., Boackle, R.J., Leu, R.W., 1991. Characterization of C1 inhibitor binding to neutrophils. Immunology 73, 95-101.
14. Colman, R.W., 1999. Biologic activities of the contact factors in vivo. Potentiation of hypotension, inflammation, and fibrinolysis, and inhibition of cell adhesion, angiogenesis and thrombosis. Thromb. Haemost. 82, 1568-1577.
15. Croner, R.S., Lehmann, T.G., Fallsehr, C., Herfarth, C., Klar, E., Kirschfink, M., 2004. C1-inhibitor reduces hepatic leukocyte-endothelial interaction and the expression of VCAM-1 in LPS-induced sepsis in the rat. Microvasc. Res. 67, 182-191.
16. Cugno, M., Bos, I., Lubbers, Y., Hack, C.E., Agostoni, A., 2001. In vitro interaction of C1-inhibitor with thrombin. Blood Coagul. Fibrinol. 12, 253-260.
17. Cugno, M., Cicardi, M., Bottasso, B., Coppola, R., Paonessa, R., Mannucci, P.M., Agostoni, A., 1997. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 89, 3213-3218.
18. Czermak, B.J., Sarma, V., Pierson, C.L., Warner, R.L., Huber-Lang, M., Bless, N.M., Schmal, H., Priedl, H.P., Ward, P.A., 1999. Protective effects of C5a blockage in sepsis. Nat. Med. 5, 788-792.
19. Dalmasso, A.P., Platt, J.L., 1993. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitromodel of xenograft hyperacute rejection by C1 inhibitor. Transplantation 56, 1171-1176.
20. De Simoni, M.G., Rossi, E., Storini, C., Pizzimenti, S., Echart, C., Bergamaschini, L., 2004. The powerful neuroprotective action of C1-inhibitor on brain ischemiareperfusion injury does not require C1q. Am. J. Pathol. 164, 1857-1863.
21. De Simoni, M.G., Storini, C., Barba, M., Catapano, L., Arabia, A.M., Rossi, E., Bergamaschini, L., 2003. Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia. J. Cereb. Blood Flow Metab. 23, 232-239.
22. de Zwaan, C., Kleine, A.H., Diris, J.H., Glatz, J.F., Wellens, H.J., Strengers, P.F., Tissings, M., Hack, C.E., van Dieijen-Visser, M.P., Hermens, W.T., 2002. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur. Heart J. 23, 1670-1677.
23. Deitch, E.A., 1997. Animal models of sepsis and shock: a review and lessons learned. Shock 9, 1-11.
24. Fattouch, K., Bianco, G., Speziale, G., Sampognaro, R., Lavalle, C., Guccione, F., Dioguardi, P., Ruvolo, G., 2007. Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study. Eur. J. Cardiothorac. Surg. 32, 326-332.
25. Feletou, M., Jamonneau, I., Germain, M., Thurieau, C., Fauchere, J.L., Villa, P., Ghezzi, P., Canet, E., 1996. Bradykinin B2 receptor involvement in rabbit and murine models of septic shock. J. Cardiovasc. Pharmacol. 27, 500-507.
26. Fiane, A.E., Videm, V., Johansen, H.T., Mellbye, O.J., Nielsen, E.W., Mollnes, T.E., 1999. C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model. Immunopharmacology 42, 231-243.
27. Fischer, M.B., Prodeus, A.P., Nicholson-Weller, A., Ma, M., Murrow, J., Reid, R.R., Warren, H.B., Lage, A.L., Moore, J.F.D., Rosen, F.S., Carroll, M.C., 1997. Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J. Immunol. 159, 976-982.
28. Folkerd, E.J., Gardner, B., Hughes-Jones, N.C., 1980. The relationship between the binding ability and the rate of activation of the complement component C1. Immunology 41, 179-185.
29. Fu, J., Lin, G., Wu, Z., Ceng, B., Wu, Y., Liang, G., Qin, G., Li, J., Chiu, I., Liu, D., 2006a. Anti-apoptotic role for C1 inhibitor in ischemia/reperfusion-inducedmyocardial cell injury. Biochem. Biophys. Res. Commun. 349, 504-512.
30. Fu, J., Lin, G., Zeng, B., Wu, Z., Wu, Y., Chu, H., Qin, G., Liang, G., Li, J., Gan, X., Yu, X., Li, C., Liu, D., 2006b. Anti-ischemia/reperfusion of C1 inhibitor in myocardial cell injury via regulation of local myocardial C3 activity. Biochem. Biophys. Res. Commun. 350, 162-168.
31. Fukuta, D., Miyagawa, S., Yamada, M., Matsunami, K., Kurihara, T., Shirasu, A., Hattori, H., Shirakura, R., 2003. Effect of various forms of the C1 esterase inhibitor (C1-INH) and DAF on complement mediated xenogeneic cell lysis. Xenotransplantation 10, 132-141.
32. Gailani, D., Renne, T., 2007. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J. Thromb. Haemost. 5, 1106-1112.
33. Giebler, R., Schmidt, U., Koch, S., Peters, J., Scherer, R., 1999. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin. Crit. Care Med. 27, 597-604.
34. Gigli, I., Mason, J.W., Colman, R.W., Austen, K.F., 1970. Interaction of plasma kallikrein with the C1 inhibitor. J. Immunol. 104, 574-581.
35. Graeter, T., Demertzis, S., Scherer, M., Langer, F., Eisele, B., Schafers, H.J., 1997. Amelioration of ischemia/reperfusion injury with C1-esterase inhibitor in a sheep lung transplant model. Ann. Haematol. 74 (Suppl.), A156.
36. Guerrero, R., Velasco, F., Rodriguez, M., Lopez, A., Rojas, R., Alvarez, M.A., Villalba, R., Rubio, V., Torres, A., Castillo, D.d., 1993. Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. J. Clin. Invest. 91, 2754-2760.
37. Hack, C.E., Ogilvie, A.C., Eisele, B., Eerenberg, A.J., Wagstaff, J., Thijs, L.G., 1993. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med. 19 (Suppl. 1), S19-S28.
38. Hack, C.E., Voerman, H.J., Eisele, B., Keinecke, H.O., Nuijens, J.H., Eerenberg, A.J., Ogilvie, A., Strack van Schijndel, R.J., Delvos, U., Thijs, L.G., 1992. C1-esterase inhibitor substitution in sepsis. Lancet 339, 378.
39. Harpel, P.C., 1981. Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J. Clin. Invest. 68, 46-55.
40. Harpel, P.C., Cooper, N.R., 1975. Studies on human plasma C1-inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin and trypsin. J. Clin. Invest. 55, 593-604.
41. Harpel, P.C., Lewin, M.F., Kaplan, A.P., 1985. Distribution of plasma kallikrein between C1 inactivator and a2-macroglobulin in plasma utilizing a new assay for a2-macroglobulin-kallikrein complexes. J. Biol. Chem. 260, 4257-4263.
42. Hauert, J., Patston, P.A., Schapira, M., 2000. C1 inhibitor cross-linking by tissue transglutaminase. J. Biol. Chem. 275, 14558-14562.
43. Hecker, J.M., Lorenz, R., Appiah, R., Vangerow, B., Loss, M., Kunz, R., Schmidtko, J., Mengel, M., Klempnauer, J., Piepenbrock, S., Dickneite, G., Neidhardt, H., Ruckoldt, H., Winkler, M., 2002. C1-inhibitor for prophylaxis of xenograft rejection after pig to cynomolgus monkey kidney transplantation. Transplantation 73, 675-677.
44. Heijnen, B.H., Straatsburg, I.H., Padilla, N.D., Van Mierlo, G.J., Hack, C.E., Van Gulik, T.M., 2006. Inhibition of classical complement activation attenuates liver ischaemia and reperfusion injury in a rat model. Clin. Exp. Immunol. 143, 15-23.
45. Horstick, G., Berg, O., Heimann, A., Gotze, O., Loos, M., Hafner, G., Bierbach, B., Petersen, S., Bhakdi, S., Darius, H., Horstick, M., Meyer, J., Kempski, O., 2001. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation 104, 3125-3131.
46. Horstick, G., Heimann, A., Gotze, O., Hafner, G., Berg, O., Bohmer, P., Becker, P., Darius, H., Rupprecht, H.J., Loos, M., Bhakdi, S., Meyer, J., Kempski, O., 1997. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces necrosis in an experimental model of ischemia reperfusion. Circulation 95, 701-708.
47. Huisman, L.G., van Griensven, J.M., Kluft, C., 1995. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb. Haemost. 73, 466-471.
48. Inderbitzin, D., Beldi, G., Avital, I., Vinci, G., Candinas, D., 2004. Local and remote ischemia-reperfusion injury is mitigated in mice overexpressing human C1 inhibitor. Eur. Surg. Res. 36, 142-147.
49. Jansen, P.M., Eisele, B., de Jong, I.W., Chang, A., Delvos, U., Taylor, J.F.B., Hack, C.E., 1998. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J. Immunol. 160, 475-484.
50. Jansen, P.M., Pixley, R.A., Brouwer, M., de Jong, I.W., Chang, A.C., Hack, C.E., Taylor Jr., F.B., Colman, R.W., 1996. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 87, 2337-2344.
51. Jiang, H., Wagner, E., Zhang, H., Frank, M.M., 2001. Complement 1 inhibitor is a regulator of the alternative complement pathway. J. Exp. Med. 194, 1609-1616.
52. Karpel-Massler, G., Fleming, S.D., Kirschfink, M., Tsokos, G.C., 2003. Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. J. Surg. Res. 115, 247-256.
53. Kerr, F.K., Thomas, A.R., Wijeyewickrema, L.C., Whisstock, J.C., Boyd, S.E., Kaiserman, D., Mathews, A.Y., Bird, P.I., Thielens, N.M., Rossi, V., Pike, R.N., 2008. Elucidation of the substrate specificity of the MASP-2 protease of the lectin complement pathway and identification of the enzyme as a major physiological target of the serpin, C1-inhibitor. Mol. Immunol. 45, 670-677.
54. Landerman, N.S., Webster, M.E., Becker, E.L., Ratcliffe, H.E., 1962. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J. Allergy 33, 330-341.
55. Lathem, W.W., Bergsbaken, T., Welch, R.A., 2004. Potentiation of C1 esterase inhibitor by StcE, ametalloprotease secreted by Escherichia coli O157:H7. J. Exp. Med. 199, 1077-1087.
56. Lathem, W.W., Grys, T.E., Witowski, S.E., Torres, S.E., Kaper, J.B., Tarr, P.I., Welch, R.A., 2002. StcE, a metalloprotease secreted by Escherichia coli O157:H7, specifically cleaves C1 esterase inhibitor. Mol. Microbiol. 45, 277-288.
57. Laurell, A.B., Martensson, U., Sjoholm, A.G., 1976. C1 subcomponent complexes in normal and pathological sera studied by crossed immunoelectrophoresis. Acta Pathol. Microbiol. Scand. 84, 455-464.
58. Lauterbach, M., Horstick, G., Plum, N., Lotz, J., Lauterbach, E., Weilemann, L.S., Kempski, O., 2007. C1-esterase inhibitor reverses functional consequences of superior mesenteric artery ischemia/reperfusion by limiting reperfusion injury and restoring microcirculatory perfusion. Shock 27, 75-83.
59. Lehmann, C., Birnbaum, J., Luhrs, C., Ruckbeil, O., Spies, C., Ziemer, S., Grundling, M., Pavlovic, D., Usichenko, T., Wendt, M., Kox, W.J., 2004. Effects of C1 esterase inhibitor administration on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation during experimental endotoxemia. Intensive Care Med. 30, 309-314.
60. Lehmann, T.G., Heger, M., Munch, S., Kirschfink, M., Klar, E., 2000. In vivo microscopy reveals thatcomplement inhibition by C1-esterase inhibitor reduces ischemia/reperfusion injury in the liver. Transpl. Int. 13 (Suppl. 1), S547-S550.
61. Liu, D., Cai, S., Gu, X., Scafidi, J., Wu, X., Davis III, A.E., 2003. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J. Immunol. 171, 2594-2601.
62. Liu, D., Cramer, C.C., Scafidi, J., Davis III, A.E., 2005a. N-linked glycosylation at Asn3 and the positively charged residues within the amino terminal domain of C1 inhibitor are required for its interaction with Salmonella typhimurium lipopolysaccharide and lipid A. Infect. Immun. 73, 4478-4487.
63. Liu, D., Gu, X., Scafidi, J., Davis III, A.E., 2004. N-linked glycosylation is required for C1 inhibitor-mediated protection from endotoxin shock inmice. Infect. Immun. 72, 1946-1955.
64. Liu, D., Lu, F., Qin, G., Fernandes, S.M., Li, J., Davis III, A.E., 2007. C1 inhibitor-mediated protection from sepsis. J. Immunol. 179, 3966-3972.
65. Liu, D., Zhang, D., Scafidi, J., Wu, X., Cramer, C.C., Davis III, A.E., 2005b. C1 inhibitor prevents gram negative bacterial lipopolysaccharide-induced vascular permeability. Blood 72, 1946-1955.
66. Marr, N., Luu, R.A., Fernandes, R.C., 2007. Bordetella pertussis binds human C1 esterase inhibitor during the virulent phase, to evade complement-mediated killing. J. Infect. Dis. 195, 585-588.
67. Matsunami, K., Miyagawa, S., Yamada, M., Yoshitatsu, M., Shirakura, R., 2000. A surface-bound form of human C1 esterase inhibitor improves xenograft rejection. Transplantation 69, 749-755.
68. Matsushita, M., Thiel, S., Jensenius, J.C., Terai, I.f.T., 2000. Proteolytic activities of two types of mannose-binding lectin associated serine protease. J. Immunol. 165, 2637-2642.
69. McConnell, D.J., 1972. Inhibitors of kallikrein in human plasma. J. Clin. Invest. 51, 1611-1623.
70. Nielsen, E.W., Mollnes, T.E., Harlan, J.M., Winn, R.K., 2002. C1-inhibitor reduces the ischaemia-reperfusion injury of skeletal muscles in mice after aortic crossclamping. Scand. J. Immunol. 56, 588-592.
71. Padilla, N.D., van Vliet, A.K., Schoots, I.G., Seron, M.V., Maas, M.A., Peltenburg, E.E., de Vries, A., Niessen, H.W., Hack, C.E., Van Gulik, T.M., 2007. C-reactive protein and natural IgM antibodies are activators of complement in a rat model of intestinal ischemia and reperfusion. Surgery 142, 722-733.
72. Patston, P.A., Schapira, M., 1997. Regulation of C1-inhibitor function by binding to type IV collagen and heparin. Biochem. Biophys. Res. Commun. 230, 597-601.
73. Petersen, S.V., Thiel, S., Jensen, L., Vorup-Jensen, T., Koch, C., Jensenius, J.C., 2000. Control of the classical and the MBL pathway of complement activation. Mol. Immunol. 37, 803-811.
74. Pixley, R.A., De La Cadena, R., Page, J.D., Kaufman, N., Wyshock, E.G., Chang, A., Taylor Jr., F.B., Colman, R.W., 1993. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J. Clin. Invest. 91, 61-68.
75. Poling, J., Oezkur, M., Kogge, K., Mengel, M., Niemann, H., Winkler, M., Haverich, A., Wiebe, K., 2006. Hyperacute rejection in ex vivo-perfused porcine lungs transgenic for human complement regulatory proteins. Transpl. Int. 19, 225-232.
76. Przemek, M., Lorenz, R., Vangerow, B., Klempnauer, J., Winkler, M., Piepenbrock, S., 2002. Pretreatment with C1-esterase inhibitor improves cardiovascular stability in small primates undergoing porcine kidney xenotransplantation. Transpl. Proc. 34, 2383.
77. Ranby, M., Bergstorf, N., Nilsson, T., 1982. Enzymatic properties of one and two chain forms of tissue plasminogen activator. Thromb. Res. 27, 175-184.
78. Ratnoff, O., Lepow, I., 1957. Some properties of an esterase derived frompreparations of the first component of complement. J. Exp. Med. 106, 327-343.
79. Ratnoff, O., Pensky, J., Ogston, D., Naff, G., 1969. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C1'r subcomponent of complement by serum C1' esterase inhibitor. J. Exp. Med. 129, 315-331.
80. Sainz, I.M., Pixley, R.A., Colman, R.W., 2007. Fifty years of research on the plasma kallikrein-kinin system: fromprotein structure and function to cell biology and in vivo pathophysiology. Thromb. Haemost. 98, 77-83.
81. Salvatierra, A., Velasco, F., Rodriguez, M., Alvarez, A., Lopez-Pedrera, R., Ramirez, R., Carracedo, J., Lopez-Rubio, F., Lopez-Pujol, A., Guerrero, R., 1997. C1-esterase inhibitor prevents early pulmonary dysfunction after lung transplantation in the dog. Am. J. Respir. Crit. Care Med. 1997, 1147-1154.
82. Schapira, M., Despland, E., Scott, C.F., Boxer, L.A., Colman, R.W., 1982. Purified human plasma kallikrein aggregates human neutrophils. J. Clin. Invest. 69, 1199-1202.
83. Schelzig, H., Simon, F., Krischer, C., Vogel, A., Abendroth, D., 2001. Ex-vivo hemoperfusion (eHPS) of pig-lungs with whole human blood: effects of complement inhibition with a soluble C1-esterase-inhibitor. Ann. Transpl. 6, 34-39.
84. Scherer, R.U., Giebler, R.M., Schmidt, U., Paar, D., Kox, W.J., 1996. The influence of C1-esterase inhibitor substitution on coagulation and cardiorespiratory parameters in an endotoxin-induced rabbit model of hypercoagulability. Seminars Thromb. Hemost. 22, 357-366.
85. Schmaier, A.H., 2007. Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system. Int. Immunopharmacol. 8, 161-165.
86. Schmidt, W., Stenzel, K., Walther, A., Gebhard, M.M., Martin, E., Schmidt, H., 1999a. Influence of C1-esterase inhibitor on tissue oxygenation of jejunal mucosa during endotoxemia. Int. J. Surg. Invest. 1, 277-283.
87. Schmidt, W., Stenzel, Z., Gebhard, M.M., Martin, E., Schmidt, H., 1999b. C1-esterase inhibitor and its effects on endotoxin-induced leukocyte adherence and plasma extravasation in postcapillary venules. Surgery 125, 280-287.
88. Schroder, C., Wu, G.S., Price, E., Johnson, J.E., Pierson, R.N.r., Azimzadeh, A.M., 2003. Hyperacute rejection of mouse lung by human blood: characterization of the model and the role of complement. Transplantation 76, 755-760.
89. Siebeck, M., Philapitsch, A., Wiesinger, H., Welter, H.F., 1987. C1-esterase in early septicemia. Prog. Clin. Biol. Res. 236A, 141-147.
90. Sim, R.B., Arlaud, G.J., Colomb, M.G., 1979a. C1 inhibitor dependent dissociation of human complement component C1 bound to immune complexes. Biochem. J. 179, 449-457.
91. Sim, R.B., Reboul, A., Arlaud, G.J., Villiers, C.L., Colomb, M.G., 1979b. Interaction of 125I-labelled complement components C1r and C1s with protease inhibitors in plasma. FEBS Lett. 97, 111-115.
92. Storini, C., Rossi, E., Marrella, V., Distaso, M., Veerhuis, R., Vergani, C., Bergamaschini, L., De Simoni, M.G., 2005. C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiol. Dis. 19, 10-17.
93. Strachan, A.J., Woodruff, T.M., Haaima, G., Fairlie, D.P., Taylor, S.M., 2000. A newsmall molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J. Immunol. 164, 6560-6565.
94. Struber, M., Hagl, C., Hirt, S.W., Cremer, J., Harringer, W., Haverich, A., 1999. C1-esterase inhibitor in graft failure after lung transplantation. Intensive CareMed. 25, 1315-1318.
95. Sulikowski, T., Patston, P.A., 2001. The inhibition of TNK-t-PA by C1-inhibitor. Blood Coagul. Fibrinol. 12, 75-77.
96. Takada, M., Nadeau, K.C., Shaw, G.D., Marquette, K.A., Tilney, N.L., 1997. The cytokineadhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. J. Clin. Invest. 99, 2682-2690.
97. Thielmann, M., Marggraf, G., Neuhauser, M., Forkel, J., Herold, U., Kamler, M., Massoudy, P., Jakob, H., 2006. Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur. J. Cardiothorac. Surg. 30, 285-293.
98. Toomayan, G.A., Chen, L.E., Jiang, H.X., Qi, W.N., Seaber, A.V., Frank, M.M., Urbaniak, J.R., 2003. C1-esterase inhibitor and anovel peptide inhibitorimprove contractile function in reperfused skeletal muscle. Microsurgery 23, 561-567.
99. van der Graaf, F., Koedam, J.A., Bouma, B.N., 1983. Inactivation of kallikrein in human plasma. J. Clin. Invest. 71, 149-158.
100. Vangerow, B., Hecker, J.M., Lorenz, R., Loss, M., Przemeck, M., Appiah, R., Schmidtko, J., Jalali, A., Rueckoldt, H., Winkler, M., 2001. C1-inhibitor for treatment of acute vascular xenograft rejection in cynomolgus recipients of h-DAF transgenic porcine kidneys. Xenotransplantation 8, 266-272.
101. Wu, G., Pfeiffer, S., Schroder, C., Zhang, T., Nguyen, B.N., Kelishadi, S., Atkinson, J.B., Schuurman, H.J., White, D.J., Azimadeh, A.M., Pierson, R.N.r., 2007. Coagulation cascade activation triggers early failure of pig hearts expressing human complement regulatory genes. Xenotransplantation 14, 34-37.
102. Zeerleder, S., Caliezi, C., Van Mierlo, G., Eerenberg-Belmer, A., Sulzer, I., Hack, C.E., Wuillemin, W.A., 2003. Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin. Diagn. Lab. Immunol. 10, 529-535.
103. Ziccardi, R., 1985. Demonstration of the interaction of native C1 with monomeric immunoglobulins and C1 inhibitor. J. Immunol. 134, 2559-2563.
104. Ziccardi, R.J., 1981. Activation of the early components of the classical complement pathway under physiological conditions. J. Immunol. 126, 1768-1773.
105. Ziccardi, R.J., Cooper, N.R., 1979. Active disassembly of the first complement component C1 by C1-inhibitor. J. Immunol. 123, 788-792.
106. Zwijnenburg, P.J.G., van der Poll, T., Florquin, S., Polfliet, M.M.J., van den Berg, T.K., Dijkstra, C.D., Roord, J.J., Hack, C.E., van Furth, A.M., 2007. C1 inhibitor treatment improves host defense in pneumococcal meningitis in rats and mice. J. Infect. Dis. 196, 115-123